ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Annexon Inc

Annexon Inc (ANNX)

5.825
0.195
(3.46%)
Closed July 23 4:00PM
5.75
-0.075
(-1.29%)
After Hours: 7:50PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
5.75
Bid
3.10
Ask
5.92
Volume
1,129,566
5.46 Day's Range 5.86
1.57 52 Week Range 8.40
Market Cap
Previous Close
5.63
Open
5.65
Last Trade
1
@
5.69
Last Trade Time
Financial Volume
$ 6,419,453
VWAP
5.6831
Average Volume (3m)
3,035,436
Shares Outstanding
92,412,866
Dividend Yield
-
PE Ratio
-4.00
Earnings Per Share (EPS)
-1.45
Revenue
-
Net Profit
-134.24M

About Annexon Inc

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmu... Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Annexon Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANNX. The last closing price for Annexon was $5.63. Over the last year, Annexon shares have traded in a share price range of $ 1.57 to $ 8.40.

Annexon currently has 92,412,866 shares outstanding. The market capitalization of Annexon is $520.28 million. Annexon has a price to earnings ratio (PE ratio) of -4.00.

ANNX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-4.958677685956.056.285.4119759945.95511359CS
40.751556.344.4519304815.25157654CS
120.9920.79831932774.767.444.230354365.5196856CS
261.3931.8807339454.368.43.8622406655.62555675CS
522.4875.84097859333.278.41.5714264665.1354196CS
156-16.79-74.489795918422.5423.611.577583485.42451752CS
260-11.1135-65.902689240116.863538.011.576125186.81128351CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
LGCBLinkage Global Inc
$ 3.6601
(-29.82%)
168k
CGBSCrown LNG Holdings Ltd
$ 0.9997
(-29.10%)
3.39M
SPECSpectaire Holdings Inc
$ 0.3962
(-24.53%)
1.87M
GSUNGolden Sun Health Technology Group Ltd
$ 5.13
(-23.66%)
158.79k
PSNLPersonalis Inc
$ 2.9808
(-22.58%)
3.11M
NVDANVIDIA Corporation
$ 123.54
(4.76%)
239M
SQQQProShares UltraPro Short QQQ
$ 8.09
(-4.37%)
183.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.15M
SERVServe Robotics Inc
$ 8.73
(15.63%)
151.56M
NCPLNetcapital Inc
$ 0.1118
(7.50%)
124.37M

ANNX Discussion

View Posts
tw0122 tw0122 2 months ago

Item?8.01.
Other Events.
On June 4, 2024, Annexon announced positive topline results from a randomized placebo-controlled pivotal Phase 3 clinical trial in patients with GBS. The Phase 3 trial met its primary endpoint, with a single infusion of ANX005 30 mg/kg achieving a statistically significant 2.4-fold improvement on the GBS-disability scale (“GBS-DS”) (proportional odds analysis, week 8, p = 0.0058). ANX005 30 mg/kg treatment also demonstrated improvements versus placebo on key secondary endpoints, including early gains in muscle strength (day 8, p < 0.0001* and week 8, p = 0.0351*) and a median of 28 fewer days on artificial ventilation (through week 26, p = 0.0356*). Additionally, ANX005 30 mg/kg demonstrated an early reduction in the prespecified analysis of serum levels of neurofilament light chain, a biomarker of nerve damage (11.2% reduction relative to placebo between weeks 2–4, p = 0.03*) and a 31-day reduction in the median time to walk independently (week 26, p = 0.0211*), each of which are important clinical care outcomes. (* nominal)
The randomized, placebo-controlled Phase 3 trial, which enrolled 241 subjects in Bangladesh and the Philippines, evaluated two doses of ANX005, 30 mg/kg and 75 mg/kg, which both delivered rapid and complete suppression of complement activity but differed in duration of C1q inhibition. The 30 mg/kg dose lasted one week and the 75 mg/kg dose lasted two to three weeks. ANX005 75 mg/kg outperformed placebo on multiple endpoints, however, it was not statistically significant on the primary endpoint of GBS-DS at week 8 (p = 0.5548). The two dose levels were evaluated based on findings in the earlier Phase 1b proof-of-concept study, which showed efficacy in pooled analysis of both shorter and longer duration of ANX005 C1q inhibition. Because classical complement drives tissue damage in the early phase of disease, while facilitating nerve repair after acute nerve injury, the strong positive Phase 3 results with the 30 mg/kg dose resulting in one week of C1q inhibition appeared to define the optimal treatment window.
The clinical safety and tolerability findings of ANX005 at both doses in the Phase 3 study support a generally well-tolerated profile with no new safety signals. The majority of adverse events were mild Grade 1 to moderate Grade 2 events. The most common treatment-related adverse events were infusion related reactions (30.4%) that were mostly mild transient rashes. There were no autoimmune related adverse events and no drug-related deaths or serious infections observed.
The GBS Phase 3 study was conducted in Bangladesh and Philippines due to the high prevalence of GBS and limited access to standard of care intravenous immunoglobulin. Based on feedback from the U.S. Food and Drug Administration (“FDA”), Annexon has initiated a real-world evidence (“RWE”) protocol with International Guillain-Barré Syndrome Outcomes Study to establish comparability between Phase 3 participants and Western patients. RWE data and a potential biologics license application submission with the FDA are expected in the first half of 2025. Annexon plans to present the Phase 3 data at the 2024 Peripheral Nerve Society Annual Meeting on June 25, 2024.
GBS is a rapid and acute neurological disease with a narrow therapeutic window that results in the hospitalization of over 22,000 people annually in the U.S. and Europe. The significant and long-term disease burden associated with GBS on patients, caregivers, hospitals and payers has led to a multi-billion-dollar annual economic cost to the U.S. healthcare system. Currently, there are no approved treatments for GBS by the FDA.
Item?9.01.
Financial Statements and Exhibits.
👍️0
Monksdream Monksdream 3 months ago
ANNX under $5
👍️0
JohnCM JohnCM 4 months ago
Looking good!
👍️0
Monksdream Monksdream 4 months ago
ANNX new 52 hi
👍️0

Your Recent History

Delayed Upgrade Clock